Amylin is the hot new target for #obesity medicines and with #amycretin, @novonordisk.bsky.social has some new data in diabetes and obesity that looks very promising. It is, however, still early days.
conscienhealth.org/2025/11/novo...

Martin Holst Lange, MD, PhD. Image courtesy of Novo Nordisk.

Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes, with meaningful HbA1c and weight reductions. EVOKE findings add valuable insight for Alzheimer’s research.

jcst2d.com/index.php/ne...

#Diabetes #ObesityCare #GLP1 #Amycretin #ClinicalTrials

Nyt vægttabsmiddel fra Novo viser lovende takter Økonomi | Politiken følger den økonomiske udvikling - bliv klogere på toldkrig, jobmarkedet, aktiekurser, boligpriser og påvirkningerne af privatøkonomien.

Smartphones aren't ONLY thing that is ever-improving tech! #Denmark co. @novo-nordisk.bsky.social annces great results for new medicine #Amycretin that in trials produced avg 14.5% #WeightLoss in only 36hrs;
If it pans out, it means more riches for DA and more thinner people

The Obesity Drug Chessboard after ADA2025 with Q2 Earnings in Play ♟️ - MidgardFinance.com Quick status check on Novo, Lilly, and rivals after ADA 2025 – just ahead of Q2 earnings. Introduction Novo Nordisk and Eli Lilly will release their Q2 results on 6 and 7 August.ADA 2025, which wrappe...

♟️ ADA 2025 reshuffled the obesity-drug board. Q2 earnings will redeploy the pieces Aug 6-7. Time to see which ones rise and which fall.
blog.midgardfinance.com/2025/07/21/t...

#Amycretin #Orforglipron #Retatrutide #CagriSema #Bimagrumab #Semaglutide #Wegovy #Zepbound
#NOVO-B.CO #LLY.US #NVO #LLY

Three new papers in @thelancet.com et offer the clearest picture yet of #amycretin and the reasons for optimism that this new #ObesityMedicine can help to lift @novonordisk.bsky.social from its funk.
conscienhealth.org/2025/07/will...

Amycretin shows promise in early trials among people with overweight, obesity The single-molecule, dual GLP-1 and amylin receptor agonist amycretin shows promising tolerability and weight loss when given orally or subcutaneously to adults with overweight or obesity.

From #ADA2025 - The single-molecule, dual GLP-1 and amylin receptor agonist #amycretin shows promising tolerability and weight loss when given orally or subcutaneously to adults with overweight or #obesity.

Full story 👉 buff.ly/xrEqw3N

#MedSky #MedNews #GLP1

Amycretin delivers unprecedented weight loss in early trial for obesity treatment Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b...

Amycretin delivers unprecedented weight loss in early trial for obesity treatment www.news-medical.net/news/2025062... #Amycretin #Obesity #WeightLoss #GLP1 #Amylin #MetabolicHealth #ClinicalTrial #Innovation #Endocrinology #Health @thelancet.com

🏆 Weight loss & CV

#Amycretin 💉 ⬇️23% @36w (🤢 ~65%, CV TBD)

#CagriSema 💉 ⬇️22.7% @68w (🌊 sema-like GI, CV running ❤️‍🔥)

#Zepbound 💉 ⬇️22.5% @72w (⬇️MACE ~20% 🫀)

#Wegovy 💉 ⬇️15% @68w (⬇️MACE ~20% 💓)

#Orforglipron 💊 ⬇️7.9% @40w in T2D (GLP-1 AEs)

#Retatrutide 💉 ⬇️24.2% @48w (GI TBD ⚠️)

Who wins 📉 + ❤️?

From @elilillyandcompany.bsky.social, @novonordisk.bsky.social, and a host of other companies, at #ADA2025 it feels a bit like a fire hose of new data on new #ObesityMedicines – including #orforglipron and #amycretin. The pipeline is full to overflowing.
conscienhealth.org/2025/06/ada2...

Amycretin vs big players 🥊🔥

🆚 Zepbound −22.5% (72w)
🆚 Wegovy −15% (68w)
🐂 Novo’s amycretin hits −23.2% in just 36w.

No plateau. Dual GLP-1/amylin agonism raising the stakes! 🚀

#NovoNordisk #Amycretin #Zepbound #Wegovy #ObesityStocks #NordicStocks

Clinical trial results showing bodyweight changes with oral amycretin vs placebo. Panel A plots mean bodyweight (kg) from screening through day 105. Amycretin groups (50 mg, 2×50 mg, 2×25 mg) all show clear weight reduction compared to stable placebo. Panel B illustrates percentage weight change from baseline (day 1) to day 105, highlighting dose-dependent effects. Greatest loss at 2×50 mg, followed by 2×25 mg, then 50 mg; minimal change with placebo. Panel C provides bar-chart summaries of day-85 results: 50 mg amycretin shows –10.4%, 2×50 mg –13.1%, 2×25 mg –12.2%, and placebo –1.2%. Estimated treatment differences vs placebo: –9.2% (50 mg), –11.8% (2×50 mg), and –11.1% (2×25 mg), all statistically significant with clear confidence intervals. The data demonstrate amycretin's robust, dose-responsive weight-loss potential compared to placebo over 12 weeks without plateau.

Oral amycretin also flexed 💊💪

In just 12 wks, −13% weight (2×50 mg), −10% (50 mg), placebo −1%. No plateau. Mild GI side-effects. Dual-agonist combo could reshape obesity treatment. 🌊

#NovoNordisk #Amycretin #ADA2025

Clinical trial results for subcutaneous amycretin vs placebo across multiple doses. Panel A plots observed mean percentage weight loss from baseline to week 36 for amycretin 60 mg, clearly outperforming placebo, which remains stable near baseline. Panel B summarizes the 36-week result: amycretin 60 mg achieved a significant estimated treatment difference (ETD) of −23.2% compared to placebo. Panel C shows percentage weight loss for lower amycretin doses (20 mg, 5 mg, 1.25 mg) versus placebo through varying durations (20-36 weeks). All doses show meaningful, sustained weight reduction, with placebo groups remaining stable or slightly increasing. Panel D summarizes ETDs: 20 mg −23.9%, 5 mg −18.6%, and 1.25 mg −11.7%, each significantly better than placebo. These data confirm robust, dose-dependent efficacy of subcutaneous amycretin for weight loss, with no plateau observed. #$NOVO-B #$NOVO-B.CO $NVO.US #$NVO $NVO

Novo Nordisk’s amycretin 🐂💉 dropped impressive data at ADA 2025:

-24% weight loss at 36 wks (60 mg) vs placebo −1%.

Lower doses also strong:
20 mg −22%
5 mg −16%
1.25 mg −10%

No plateau yet; Phase 3 ahead! 🔥

#NovoNordisk #ADA2025 #Amycretin

Novo Nordisk's Amycretin Moves to Phase 3 Development for Obesity Treatment Following Promising Trial Results Novo Nordisk is advancing its obesity medication amycretin to phase 3 trials based on successful phase 1b/2a results that indicated significant weight loss in participants.

Novo Nordisk's Amycretin Moves to Phase 3 Development for Obesity Treatment Following Promising Trial Results #United_States #Novo_Nordisk #Plainsboro #Obesity_Treatment #amycretin

In announcing plans for phase 3 trials of both oral and injectable #amycretin and data to present at #ADASciSessions, @novonordisk is making it plain that the drumbeat for this innovative dual agonist will grow.
conscienhealth.org/2025/06/the-...

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year (Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese. The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker’s next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin. Weekly injections of the drug helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results published in January. Last year, the pill version helped patients lose up to 13.1% of their weight after 12 weeks in early-stage trial. Novo is also developing another two-drug combination, known as CagriSema, which, too, targets the amylin hormone. The company has launched a new late-stage trial for the drug, the U.S. government’s trial database showed this week, as it tries to reassure the market of its potential after disappointing data from two previous studies. Novo had positioned CagriSema as a more potent successor to its blockbuster obesity treatment Wegovy, but lower-than-expected weight loss stoked worries that Eli Lilly (NYSE:LLY) may be gaining an edge over the company in the market for such drugs. Should you invest $2,000 in LLY right now? Before you buy stock in LLY, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is LLY one of them?

Click Subscribe #NovoNordisk #ObesityResearch #ClinicalTrials #Amycretin #Pharmaceuticals

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese.

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year - www.reuters.com/business/hea... #$NOVO-B.CO #$NVO.NY #$NVO #Amycretin

Interesting in that #amycretin is a dual amylin/GLP-1 analog unlike #cagrisema which contains 2 separate analogs. Results in ph2 comparable to #retatrutide for TBW Loss and planned for both sc and PO
#liversky #medsky

Novo Nordisk headquarters. Courtesy of News Øresund - Johan Wessman - Licensed under CC BY 3.0. Photo link: Flickr. https://creativecommons.org/licenses/by/3.0/ https://www.flickr.com/photos/newsoresund/29190030262

Novo Nordisk's amycretin trial shows promising weight loss: 9.7% at 20 weeks, 16.2% at 28 weeks, and 22% at 36 weeks. The drug now faces further trials and FDA approval.

jcst2d.com/index.php?vi...

#NovoNordisk #Amycretin #WeightLoss #ObesityTreatment #ClinicalTrials

The juicy #obesity #DrugDevelopment news of the week came from Novo Nordisk announcing topline weight loss with #amycretin – 22% after 36 weeks. Similar numbers for CagriSema were recently seen as disappointing. But cheers greeted these new results. 🤷‍♀️
conscienhealth.org/2025/01/amyc...

News Details

New #obesity data: $NVO subQ #Amycretin shows up to 24% pbo-adjusted WL at 36 wks, which seems competitive with $LLY #retatrutide
www.novonordisk.com/content/nnco...